Global Treprostinil Sodium Market - Growth Opportunities, Competitive Insights, and Forecast to 2030

 The Business Research Company’s 2026 market reports introduce new features such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, all designed to enhance the depth, usability, and strategic value of the insights provided.

How Is the Treprostinil Sodium Market Growth Forecast from 2026 to 2030?
The treprostinil sodium market size has grown strongly in recent years. It will grow from $1.25 billion in 2025 to $1.37 billion in 2026 at a compound annual growth rate (CAGR) of 9.5%. The growth in the historic period can be attributed to clinical effectiveness of prostacyclin therapy, expansion of pah diagnosis, hospital-based pah treatment, limited alternative therapies, improved survival outcomes.

The treprostinil sodium market size is expected to see strong growth in the next few years. It will grow to $1.97 billion in 2030 at a compound annual growth rate (CAGR) of 9.4%. The growth in the forecast period can be attributed to rising pah prevalence, increasing long-term treatment adoption, expansion of inhalable and oral formulations, growing specialty clinic presence, rising awareness of pah. Major trends in the forecast period include rising use of prostacyclin analog therapies, increasing focus on pulmonary arterial hypertension, expansion of home-based pah treatment, growing adoption of multiple drug delivery routes, increased demand for long-term pah management.

Claim your free report sample now:
https://www.thebusinessresearchcompany.com/report/treprostinil-sodium-global-market-report

Which Key Growth Contributors Will Drive the Treprostinil Sodium Market in the Next Decade?
The increasing cases of pulmonary diseases are expected to propel the growth of the treprostinil sodium market going forward. Pulmonary diseases are conditions that impact the lungs and respiratory system, disrupting breathing and oxygen flow. The increasing cases of pulmonary disease are due to factors such as air pollution, smoking, environmental toxins, and a growing aging population. Treprostinil sodium is a vasodilator that relaxes lung blood vessels, reduces pressure, improves breathing, and offers flexible treatment for pulmonary diseases. For instance, in June 2025, according to the Office for Health Improvement & Disparities, a UK-based government agency, the rate of emergency hospital admissions for respiratory diseases in England rose by 7% between the financial years ending 2023 and 2024. Therefore, increasing cases of pulmonary diseases are driving the growth of the treprostinil sodium market.

What Are the Main Segments of the Treprostinil Sodium Market?
The treprostinil sodium market covered in this report is segmented –

1) By Product Type: Injectable, Inhalable, Oral
2) By Applications: Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension, Other Applications
3) By Distribution Channel: Hospitals, Specialty Clinics, Online Pharmacies, Retail Pharmacies

Subsegments:
1) By Injectable: Subcutaneous Injection, Intravenous Infusion
2) By Inhalable: Inhalation Aerosol, Nebulizer Solution
3) By Oral: Extended-Release Tablets, Oral Suspension

Which Trends Are Expected to Redefine the Treprostinil Sodium Market Landscape?
Major companies operating in the treprostinil sodium market are focusing on developing advanced pulmonary arterial hypertension such as pulmonary vasodilator prostacyclin analogy injection to enhance pulmonary hemodynamic control and symptom management in patients with pulmonary arterial hypertension (PAH). Pulmonary vasodilator prostacyclin analog injection refers to a biologically synthesized formulation of prostacyclin or its analogy that is administered intravenously or subcutaneously to dilate pulmonary arteries, reduce pulmonary vascular resistance, and improve blood flow in patients with pulmonary arterial hypertension (PAH). For instance, in April 2023, Dr. Reddy's Laboratories, an India-based pharmaceutical company, announced the launch of Treprostinil Injection in the U.S. market approved by the Food and Drug Administration, a US-based government agency. Treprostinil injection is a therapeutic equivalent generic version of Remodulin (treprostinil) injection that belongs to a group of agents called prostacyclin mimetics used for the treatment of pulmonary arterial hypertension to diminish symptoms associated with exercise. It is supplied in vials of 20 mg/20 mL, 50 mg/20 mL, 100 mg/20 mL, or 200 mg/20 mL.

Which Are the Key Companies Shaping the Treprostinil Sodium Market Landscape?
Major companies operating in the treprostinil sodium market are United Therapeutics Corporation, Liquidia Corporation, Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Dr. Reddy's Laboratories Ltd., Mylan Laboratories Limited, Alembic Pharmaceuticals Ltd., Euroapi SA, Cipla Limited, Lupin Limited, Sun Pharmaceutical Industries Ltd., Endo International plc, ChemWerth Inc., LGM Pharma, Simson Pharma Limited, YONSUNG Fine Chemicals Co. Ltd., Nuray Chemicals Private Limited, KPS Chemicals Pharmaceuticals, Farbe Firma Pvt. Ltd., Aurobindo Pharma Limited

Get the full treprostinil sodium market report here:
https://www.thebusinessresearchcompany.com/report/treprostinil-sodium-global-market-report

Which region represents the fastest-growing market for the Treprostinil Sodium Market?
North America was the largest region in the treprostinil sodium market in 2025. The regions covered in the treprostinil sodium market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Contact Us:

The Business Research Company: Global Market Research Reports & Consulting | The Business Research Company
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info

Follow Us On:

LinkedIn: The Business Research Company | LinkedIn